Phase II study of fluorouracil and its modulation in advanced colorectal cancer: A Southwest Oncology Group study

C. G. Leichman, T. R. Fleming, F. M. Muggia, C. M. Tangen, B. Ardalan, J. H. Doroshow, Frederick J Meyers, R. F. Holcombe, G. R. Weiss, A. Mangalik, J. S. Macdonald

Research output: Contribution to journalArticle

327 Citations (Scopus)

Abstract

Purpose: A variety of fluorinated pyrimidine-based regimens for the treatment of disseminated colorectal cancer have been presented in the medical literature. The Southwest Oncology Group designed a screening trial of seven regimens of fluorouracil (5-FU) to assess efficacy and toxicity afforded by biochemical modulation or schedule variations. Patients and Methods: Six hundred twenty patients were entered onto this trial between August 1989 and January 1993. Eligible patients were classified as having recurrent or disseminated disease that was measurable or nonmeasurable. All eligible patients were evaluated for toxicity and survival; patients with measurable disease were evaluated for response according to standard criteria. Results: No regimen achieved a higher response rate than single- agent bolus 5-FU. Eighty-four percent of patients have been monitored until death. The median survival time for the entire cohort is 14 months. Survival hazards ratios showed a positive trend in favor of the unmodulated infusion regimens, while high-grade toxicities occurred more frequently in the 5-FU bolus arms. The major high-grade toxicities were granulocytopenia and diarrhea. Conclusion: In this trial, no regimen provided substantial improvement relative to 5-FU bolus or single-agent therapy for either response or survival in the treatment of disseminated colorectal cancer. The single-agent infusion regimens demonstrated the most encouraging results with a favorable toxicity profile and a 2-month longer survival duration than 5- FU bolus therapy.

Original languageEnglish (US)
Pages (from-to)1303-1311
Number of pages9
JournalJournal of Clinical Oncology
Volume13
Issue number6
StatePublished - Jun 1995
Externally publishedYes

Fingerprint

Fluorouracil
Colorectal Neoplasms
Survival
Agranulocytosis
Therapeutics
Diarrhea
Appointments and Schedules

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Leichman, C. G., Fleming, T. R., Muggia, F. M., Tangen, C. M., Ardalan, B., Doroshow, J. H., ... Macdonald, J. S. (1995). Phase II study of fluorouracil and its modulation in advanced colorectal cancer: A Southwest Oncology Group study. Journal of Clinical Oncology, 13(6), 1303-1311.

Phase II study of fluorouracil and its modulation in advanced colorectal cancer : A Southwest Oncology Group study. / Leichman, C. G.; Fleming, T. R.; Muggia, F. M.; Tangen, C. M.; Ardalan, B.; Doroshow, J. H.; Meyers, Frederick J; Holcombe, R. F.; Weiss, G. R.; Mangalik, A.; Macdonald, J. S.

In: Journal of Clinical Oncology, Vol. 13, No. 6, 06.1995, p. 1303-1311.

Research output: Contribution to journalArticle

Leichman, CG, Fleming, TR, Muggia, FM, Tangen, CM, Ardalan, B, Doroshow, JH, Meyers, FJ, Holcombe, RF, Weiss, GR, Mangalik, A & Macdonald, JS 1995, 'Phase II study of fluorouracil and its modulation in advanced colorectal cancer: A Southwest Oncology Group study', Journal of Clinical Oncology, vol. 13, no. 6, pp. 1303-1311.
Leichman CG, Fleming TR, Muggia FM, Tangen CM, Ardalan B, Doroshow JH et al. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: A Southwest Oncology Group study. Journal of Clinical Oncology. 1995 Jun;13(6):1303-1311.
Leichman, C. G. ; Fleming, T. R. ; Muggia, F. M. ; Tangen, C. M. ; Ardalan, B. ; Doroshow, J. H. ; Meyers, Frederick J ; Holcombe, R. F. ; Weiss, G. R. ; Mangalik, A. ; Macdonald, J. S. / Phase II study of fluorouracil and its modulation in advanced colorectal cancer : A Southwest Oncology Group study. In: Journal of Clinical Oncology. 1995 ; Vol. 13, No. 6. pp. 1303-1311.
@article{48fb19b0dc7e4db9acc1888cc480c3bf,
title = "Phase II study of fluorouracil and its modulation in advanced colorectal cancer: A Southwest Oncology Group study",
abstract = "Purpose: A variety of fluorinated pyrimidine-based regimens for the treatment of disseminated colorectal cancer have been presented in the medical literature. The Southwest Oncology Group designed a screening trial of seven regimens of fluorouracil (5-FU) to assess efficacy and toxicity afforded by biochemical modulation or schedule variations. Patients and Methods: Six hundred twenty patients were entered onto this trial between August 1989 and January 1993. Eligible patients were classified as having recurrent or disseminated disease that was measurable or nonmeasurable. All eligible patients were evaluated for toxicity and survival; patients with measurable disease were evaluated for response according to standard criteria. Results: No regimen achieved a higher response rate than single- agent bolus 5-FU. Eighty-four percent of patients have been monitored until death. The median survival time for the entire cohort is 14 months. Survival hazards ratios showed a positive trend in favor of the unmodulated infusion regimens, while high-grade toxicities occurred more frequently in the 5-FU bolus arms. The major high-grade toxicities were granulocytopenia and diarrhea. Conclusion: In this trial, no regimen provided substantial improvement relative to 5-FU bolus or single-agent therapy for either response or survival in the treatment of disseminated colorectal cancer. The single-agent infusion regimens demonstrated the most encouraging results with a favorable toxicity profile and a 2-month longer survival duration than 5- FU bolus therapy.",
author = "Leichman, {C. G.} and Fleming, {T. R.} and Muggia, {F. M.} and Tangen, {C. M.} and B. Ardalan and Doroshow, {J. H.} and Meyers, {Frederick J} and Holcombe, {R. F.} and Weiss, {G. R.} and A. Mangalik and Macdonald, {J. S.}",
year = "1995",
month = "6",
language = "English (US)",
volume = "13",
pages = "1303--1311",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "6",

}

TY - JOUR

T1 - Phase II study of fluorouracil and its modulation in advanced colorectal cancer

T2 - A Southwest Oncology Group study

AU - Leichman, C. G.

AU - Fleming, T. R.

AU - Muggia, F. M.

AU - Tangen, C. M.

AU - Ardalan, B.

AU - Doroshow, J. H.

AU - Meyers, Frederick J

AU - Holcombe, R. F.

AU - Weiss, G. R.

AU - Mangalik, A.

AU - Macdonald, J. S.

PY - 1995/6

Y1 - 1995/6

N2 - Purpose: A variety of fluorinated pyrimidine-based regimens for the treatment of disseminated colorectal cancer have been presented in the medical literature. The Southwest Oncology Group designed a screening trial of seven regimens of fluorouracil (5-FU) to assess efficacy and toxicity afforded by biochemical modulation or schedule variations. Patients and Methods: Six hundred twenty patients were entered onto this trial between August 1989 and January 1993. Eligible patients were classified as having recurrent or disseminated disease that was measurable or nonmeasurable. All eligible patients were evaluated for toxicity and survival; patients with measurable disease were evaluated for response according to standard criteria. Results: No regimen achieved a higher response rate than single- agent bolus 5-FU. Eighty-four percent of patients have been monitored until death. The median survival time for the entire cohort is 14 months. Survival hazards ratios showed a positive trend in favor of the unmodulated infusion regimens, while high-grade toxicities occurred more frequently in the 5-FU bolus arms. The major high-grade toxicities were granulocytopenia and diarrhea. Conclusion: In this trial, no regimen provided substantial improvement relative to 5-FU bolus or single-agent therapy for either response or survival in the treatment of disseminated colorectal cancer. The single-agent infusion regimens demonstrated the most encouraging results with a favorable toxicity profile and a 2-month longer survival duration than 5- FU bolus therapy.

AB - Purpose: A variety of fluorinated pyrimidine-based regimens for the treatment of disseminated colorectal cancer have been presented in the medical literature. The Southwest Oncology Group designed a screening trial of seven regimens of fluorouracil (5-FU) to assess efficacy and toxicity afforded by biochemical modulation or schedule variations. Patients and Methods: Six hundred twenty patients were entered onto this trial between August 1989 and January 1993. Eligible patients were classified as having recurrent or disseminated disease that was measurable or nonmeasurable. All eligible patients were evaluated for toxicity and survival; patients with measurable disease were evaluated for response according to standard criteria. Results: No regimen achieved a higher response rate than single- agent bolus 5-FU. Eighty-four percent of patients have been monitored until death. The median survival time for the entire cohort is 14 months. Survival hazards ratios showed a positive trend in favor of the unmodulated infusion regimens, while high-grade toxicities occurred more frequently in the 5-FU bolus arms. The major high-grade toxicities were granulocytopenia and diarrhea. Conclusion: In this trial, no regimen provided substantial improvement relative to 5-FU bolus or single-agent therapy for either response or survival in the treatment of disseminated colorectal cancer. The single-agent infusion regimens demonstrated the most encouraging results with a favorable toxicity profile and a 2-month longer survival duration than 5- FU bolus therapy.

UR - http://www.scopus.com/inward/record.url?scp=0029012118&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029012118&partnerID=8YFLogxK

M3 - Article

C2 - 7751875

AN - SCOPUS:0029012118

VL - 13

SP - 1303

EP - 1311

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 6

ER -